Sartorius has signed a non-exclusive licensing deal with Dutch
biotech firms Crucell and DSM for the use of their PER C6 cell
culture technology which could result in the creation of a new
bioprocessing platform combined with disposable...
Just weeks after announcing intentions to snap up biologics firm
MedImmune, AstraZeneca has acquired DSM's old biologics
manufacturing facility in Montreal, Canada, a site that's been
gathering dust since it was mothballed...
Technology and services provider Althea Technologies has stepped
closer to a significant increase in manufacturing capacity as it
announces the completion of the first phase of construction at its
new San Diego facility.
Swiss contract manufacturer Lonza has announced it will invest
around $300m (€220m) in the expansion of its US biomanufacturing
plant, just two weeks after kicking off the construction of a
similar facility in Singapore.
A Brazilian firm has signed a licensing deal to take advantage of a
biopharmaceutical manufacturing technology which will allow the
company to locally manufacture complex biopharmaceuticals destined
for the South American market.
This week Lonza took over the reigns of two new US business units
from Cambrex after completing the largest acquisition in its
company history and also announced a capability expansion at its
Czech Republic site.
US-based firm Xcellerex yesterday announced it has completed the
second half of a $20m (€15.4m) financing deal, raising $11m to
speed up commercialisation of its innovative disposable
manufacturing technology for vaccines and biotherapeutics.